BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Qian Y, Gong Y, Fan Z, Luo G, Huang Q, Deng S, Cheng H, Jin K, Ni Q, Yu X, Liu C. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma. J Hematol Oncol 2020;13:130. [PMID: 33008426 DOI: 10.1186/s13045-020-00958-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Abrams SL, Akula SM, Steelman LS, Follo ML, Cocco L, Ratti S, Martelli AM, Libra M, Falzone L, Candido S, Montalto G, Cervello M, Lombardi P, McCubrey JA. Effects of the MDM2 inhibitor Nutlin-3a on sensitivity of pancreatic cancer cells to berberine and modified berberines in the presence and absence of WT-TP53. Adv Biol Regul 2021;:100840. [PMID: 34866036 DOI: 10.1016/j.jbior.2021.100840] [Reference Citation Analysis]
2 Hafezi S, Saber-Ayad M, Abdel-Rahman WM. Highlights on the Role of KRAS Mutations in Reshaping the Microenvironment of Pancreatic Adenocarcinoma. Int J Mol Sci 2021;22:10219. [PMID: 34638560 DOI: 10.3390/ijms221910219] [Reference Citation Analysis]
3 Hua H, Zhang H, Chen J, Wang J, Liu J, Jiang Y. Targeting Akt in cancer for precision therapy. J Hematol Oncol 2021;14:128. [PMID: 34419139 DOI: 10.1186/s13045-021-01137-8] [Reference Citation Analysis]
4 Ay S, Atcı MM, Arıkan R, Dülgar Ö, Özyükseler DT, Paksoy N, Doğan İ, Öztosun B, Taştekin D, Öven BB, Gümüş M. FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer. J Chemother 2022;:1-7. [PMID: 35037592 DOI: 10.1080/1120009X.2022.2026125] [Reference Citation Analysis]
5 Chen S, Chen C, Hu Y, Song G, Shen X. The diverse roles of circular RNAs in pancreatic cancer. Pharmacol Ther 2021;226:107869. [PMID: 33895187 DOI: 10.1016/j.pharmthera.2021.107869] [Reference Citation Analysis]
6 Tang P, Qu W, Wu D, Chen S, Liu M, Chen W, Ai Q, Tang H, Zhou H. Identifying and Validating an Acidosis-Related Signature Associated with Prognosis and Tumor Immune Infiltration Characteristics in Pancreatic Carcinoma. J Immunol Res 2021;2021:3821055. [PMID: 34993253 DOI: 10.1155/2021/3821055] [Reference Citation Analysis]
7 Chen ZG, Wang Y, Fong WP, Hu MT, Liang JY, Wang L, Li YH. A quantitative score of immune cell infiltration predicts the prognosis in pancreatic ductal adenocarcinoma. Int Immunopharmacol 2021;98:107890. [PMID: 34174701 DOI: 10.1016/j.intimp.2021.107890] [Reference Citation Analysis]
8 Malvi D, Vasuri F, Maloberti T, Sanza V, De Leo A, Fornelli A, Masetti M, Benini C, Lombardi R, Offi MF, Di Marco M, Ravaioli M, Fiorino S, Franceschi E, Brandes AA, Jovine E, D’errico A, Tallini G, de Biase D. Molecular Characterization of Pancreatic Ductal Adenocarcinoma Using a Next-Generation Sequencing Custom-Designed Multigene Panel. Diagnostics 2022;12:1058. [DOI: 10.3390/diagnostics12051058] [Reference Citation Analysis]
9 Nikas IP, Mountzios G, Sydney GI, Ioakim KJ, Won J, Papageorgis P. Evaluating Pancreatic and Biliary Neoplasms with Small Biopsy-Based Next Generation Sequencing (NGS): Doing More with Less. Cancers 2022;14:397. [DOI: 10.3390/cancers14020397] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Kang BW, Chau I. Emerging agents for metastatic pancreatic cancer: spotlight on early phase clinical trials. Expert Opin Investig Drugs 2021;:1-19. [PMID: 34727804 DOI: 10.1080/13543784.2021.1995354] [Reference Citation Analysis]
11 Safe S, Shrestha R, Mohankumar K, Howard M, Hedrick E, Abdelrahim M. Transcription factors specificity protein and nuclear receptor 4A1 in pancreatic cancer. World J Gastroenterol 2021; 27(38): 6387-6398 [PMID: 34720529 DOI: 10.3748/wjg.v27.i38.6387] [Reference Citation Analysis]
12 Huang C, Iovanna J, Santofimia-Castaño P. Targeting Fibrosis: The Bridge That Connects Pancreatitis and Pancreatic Cancer. Int J Mol Sci 2021;22:4970. [PMID: 34067040 DOI: 10.3390/ijms22094970] [Reference Citation Analysis]
13 Traub B, Link KH, Kornmann M. Curing pancreatic cancer. Semin Cancer Biol 2021:S1044-579X(21)00160-7. [PMID: 34062264 DOI: 10.1016/j.semcancer.2021.05.030] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 He C, Duan L, Zheng H, Li-Ling J, Song L, Li L. Graph convolutional network approach to discovering disease-related circRNA-miRNA-mRNA axes. Methods 2021:S1046-2023(21)00246-2. [PMID: 34758394 DOI: 10.1016/j.ymeth.2021.10.006] [Reference Citation Analysis]
15 Visani M, Acquaviva G, De Leo A, Sanza V, Merlo L, Maloberti T, Brandes AA, Franceschi E, Di Battista M, Masetti M, Jovine E, Fiorino S, Pession A, Tallini G, de Biase D. Molecular alterations in pancreatic tumors. World J Gastroenterol 2021; 27(21): 2710-2726 [PMID: 34135550 DOI: 10.3748/wjg.v27.i21.2710] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
16 Abraham E, Trainor N, Ostrout N, Hewitt MM. Cell therapy products are revolutionizing multiple therapeutic areas; to maintain this pace of innovation, manufacturing solutions must adapt. Current Opinion in Biomedical Engineering 2021;20:100340. [DOI: 10.1016/j.cobme.2021.100340] [Reference Citation Analysis]
17 Zhu XR, Peng SQ, Wang L, Chen XY, Feng CX, Liu YY, Chen MB. Identification of phosphoenolpyruvate carboxykinase 1 as a potential therapeutic target for pancreatic cancer. Cell Death Dis 2021;12:918. [PMID: 34620839 DOI: 10.1038/s41419-021-04201-w] [Reference Citation Analysis]
18 Wang S, Zheng Y, Yang F, Zhu L, Zhu XQ, Wang ZF, Wu XL, Zhou CH, Yan JY, Hu BY, Kong B, Fu DL, Bruns C, Zhao Y, Qin LX, Dong QZ. The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives. Signal Transduct Target Ther 2021;6:249. [PMID: 34219130 DOI: 10.1038/s41392-021-00659-4] [Reference Citation Analysis]
19 Kisling SG, Natarajan G, Pothuraju R, Shah A, Batra SK, Kaur S. Implications of prognosis-associated genes in pancreatic tumor metastasis: lessons from global studies in bioinformatics. Cancer Metastasis Rev 2021;40:721-38. [PMID: 34591244 DOI: 10.1007/s10555-021-09991-1] [Reference Citation Analysis]
20 Wu J, Wang L, Xu J. The role of pyroptosis in modulating the tumor immune microenvironment. Biomark Res 2022;10:45. [PMID: 35739593 DOI: 10.1186/s40364-022-00391-3] [Reference Citation Analysis]
21 Li Q, Shen Z, Shen Y, Deng H, Shen Y, Wang J, Zhan G, Zhou C. Identification of immune-related lncRNA panel for predicting immune checkpoint blockade and prognosis in head and neck squamous cell carcinoma. J Clin Lab Anal 2022;:e24484. [PMID: 35561269 DOI: 10.1002/jcla.24484] [Reference Citation Analysis]
22 Zhu S, Zhang T, Zheng L, Liu H, Song W, Liu D, Li Z, Pan CX. Combination strategies to maximize the benefits of cancer immunotherapy. J Hematol Oncol 2021;14:156. [PMID: 34579759 DOI: 10.1186/s13045-021-01164-5] [Reference Citation Analysis]
23 Razzano D, Bouza SJ, Hernandez PV, Wang M, Robert ME, Walther Z, Cai G. Comprehensive molecular profiling of pancreatic ductal adenocarcinoma in FNA, biopsy, and resection specimens. Cancer Cytopathol 2022. [PMID: 35511415 DOI: 10.1002/cncy.22589] [Reference Citation Analysis]
24 Abrams SL, Duda P, Akula SM, Steelman LS, Follo ML, Cocco L, Ratti S, Martelli AM, Montalto G, Emma MR, Cervello M, Rakus D, Gizak A, Mccubrey JA. Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53. Cells 2022;11:794. [DOI: 10.3390/cells11050794] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
25 Xu Q, Chen S, Hu Y, Huang W. Single-cell RNA transcriptome reveals the intra-tumoral heterogeneity and regulators underlying tumor progression in metastatic pancreatic ductal adenocarcinoma. Cell Death Discov 2021;7:331. [PMID: 34732701 DOI: 10.1038/s41420-021-00663-1] [Reference Citation Analysis]
26 Guo Y, Wang R, Li J, Song Y, Min J, Zhao T, Hua L, Shi J, Zhang C, Ma P, Yang C, Zhu L, Gan D, Li S, Liu X, Su H. Comprehensive Analysis of m6A RNA Methylation Regulators and the Immune Microenvironment to Aid Immunotherapy in Pancreatic Cancer. Front Immunol 2021;12:769425. [PMID: 34804059 DOI: 10.3389/fimmu.2021.769425] [Reference Citation Analysis]
27 Tarannum M, Vivero-Escoto JL. Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment. Adv Drug Deliv Rev 2022;187:114357. [PMID: 35605679 DOI: 10.1016/j.addr.2022.114357] [Reference Citation Analysis]
28 Wang L, Liu Z, Zhu R, Liang R, Wang W, Li J, Zhang Y, Guo C, Han X, Sun Y. Multi-omics landscape and clinical significance of a SMAD4-driven immune signature: implications for risk stratification and frontline therapies in pancreatic cancer. Computational and Structural Biotechnology Journal 2022. [DOI: 10.1016/j.csbj.2022.02.031] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Dujardin P, Baginska AK, Urban S, Grüner BM. Unraveling Tumor Heterogeneity by Using DNA Barcoding Technologies to Develop Personalized Treatment Strategies in Advanced-Stage PDAC. Cancers (Basel) 2021;13:4187. [PMID: 34439341 DOI: 10.3390/cancers13164187] [Reference Citation Analysis]
30 Li Y, Al Hallak MN, Philip PA, Azmi AS, Mohammad RM. Non-Coding RNAs in Pancreatic Cancer Diagnostics and Therapy: Focus on lncRNAs, circRNAs, and piRNAs. Cancers (Basel) 2021;13:4161. [PMID: 34439315 DOI: 10.3390/cancers13164161] [Reference Citation Analysis]
31 Zhang J, Shao C, Yin Y, Sun Q, Li Y, Zha Y, Li M, Hu B, Bukhari I. Hypoxia-Related Signature Is a Prognostic Biomarker of Pancreatic Cancer. Disease Markers 2022;2022:1-16. [DOI: 10.1155/2022/6449997] [Reference Citation Analysis]
32 Liu XY, Guo CH, Xi ZY, Xu XQ, Zhao QY, Li LS, Wang Y. Histone methylation in pancreatic cancer and its clinical implications. World J Gastroenterol 2021; 27(36): 6004-6024 [PMID: 34629816 DOI: 10.3748/wjg.v27.i36.6004] [Reference Citation Analysis]
33 Dai CJ, Cao YT, Huang F, Wang YG. Multiple roles of mothers against decapentaplegic homolog 4 in tumorigenesis, stem cells, drug resistance, and cancer therapy. World J Stem Cells 2022; 14(1): 41-53 [DOI: 10.4252/wjsc.v14.i1.41] [Reference Citation Analysis]
34 Miquel M, Zhang S, Pilarsky C. Pre-clinical Models of Metastasis in Pancreatic Cancer. Front Cell Dev Biol 2021;9:748631. [PMID: 34778259 DOI: 10.3389/fcell.2021.748631] [Reference Citation Analysis]
35 Zhang Q, Lu J, Jia M, Ma Y, Sun M, Chen X, Ma X, Yang Y, Kang J, Zhang X, Paiella S, Katz MHG, Tsuchida K, Schattner M, Du S. Evaluation of the reporting quality of clinical practice guidelines on pancreatic cancer using the RIGHT checklist. Ann Transl Med 2021;9:1088. [PMID: 34423000 DOI: 10.21037/atm-21-2644] [Reference Citation Analysis]
36 Sturm N, Ettrich TJ, Perkhofer L. The Impact of Biomarkers in Pancreatic Ductal Adenocarcinoma on Diagnosis, Surveillance and Therapy. Cancers (Basel) 2022;14:217. [PMID: 35008381 DOI: 10.3390/cancers14010217] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Stoof J, Harrold E, Mariottino S, Lowery MA, Walsh N. DNA Damage Repair Deficiency in Pancreatic Ductal Adenocarcinoma: Preclinical Models and Clinical Perspectives. Front Cell Dev Biol 2021;9:749490. [PMID: 34712667 DOI: 10.3389/fcell.2021.749490] [Reference Citation Analysis]
38 Wang Z, Zou W, Wang F, Zhang G, Chen K, Hu M, Liu R. Identification of the immune cell infiltration landscape in pancreatic cancer to assist immunotherapy. Future Oncol 2021. [PMID: 34346253 DOI: 10.2217/fon-2021-0495] [Reference Citation Analysis]
39 Mollinedo F, Gajate C. Direct Endoplasmic Reticulum Targeting by the Selective Alkylphospholipid Analog and Antitumor Ether Lipid Edelfosine as a Therapeutic Approach in Pancreatic Cancer. Cancers (Basel) 2021;13:4173. [PMID: 34439330 DOI: 10.3390/cancers13164173] [Reference Citation Analysis]
40 Huang X, Zhang G, Liang T. Subtyping for pancreatic cancer precision therapy. Trends in Pharmacological Sciences 2022. [DOI: 10.1016/j.tips.2022.03.005] [Reference Citation Analysis]
41 Ono M, Ono Y, Nakamura T, Tsuchikawa T, Kuraya T, Kuwabara S, Nakanishi Y, Asano T, Matsui A, Tanaka K, Ebihara Y, Kurashima Y, Noji T, Murakami S, Shichinohe T, Mitsuhashi T, Omori Y, Furukawa T, Taniue K, Suzuki M, Sugitani A, Karasaki H, Mizukami Y, Hirano S. Predictors of Long-Term Survival in Pancreatic Ductal Adenocarcinoma after Pancreatectomy: TP53 and SMAD4 Mutation Scoring in Combination with CA19-9. Ann Surg Oncol. [DOI: 10.1245/s10434-022-11630-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Zhang D, Lindstrom A, Kim EJ, Hwang C, Hall ML, Lin T, Li Y. SEMA3C Supports Pancreatic Cancer Progression by Regulating the Autophagy Process and Tumor Immune Microenvironment. Front Oncol 2022;12:890154. [DOI: 10.3389/fonc.2022.890154] [Reference Citation Analysis]
43 Al-Mansoori L, Elsinga P, Goda SK. Bio-vehicles of cytotoxic drugs for delivery to tumor specific targets for cancer precision therapy. Biomed Pharmacother 2021;144:112260. [PMID: 34607105 DOI: 10.1016/j.biopha.2021.112260] [Reference Citation Analysis]
44 Ragone A, Salzillo A, Spina A, Naviglio S, Sapio L. Integrating Gemcitabine-Based Therapy With AdipoRon Enhances Growth Inhibition in Human PDAC Cell Lines. Front Pharmacol 2022;13:837503. [PMID: 35273510 DOI: 10.3389/fphar.2022.837503] [Reference Citation Analysis]